NEW YORK (GenomeWeb News) – Genetic testing company Interleukin Genetics reported after the close of the market on Wednesday a 45 percent drop year over year in its third-quarter revenues.

Total revenues during the quarter fell to $420,011 from $765,416 as genetic testing service revenues fell to $383,064 from $731,194 a year ago, a 48 percent decrease. Other revenues inched up 8 percent to $36,947 from $34,222.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.